TY - JOUR
T1 - The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992)
AU - Baas, P.
AU - Ardizzoni, A.
AU - Grossi, F.
AU - Nackaerts, K.
AU - Numico, G.
AU - van Marck, E.
AU - van de Vijver, M.
AU - Monetti, F.
AU - Smid-Geirnaerdt, M. J. A.
AU - van Zandwijk, N.
AU - Debruyne, C.
AU - Legrand, C.
AU - Giaccone, G.
PY - 2003
Y1 - 2003
N2 - We investigated the activity and toxicity of raltitrexed (Tomudex) as a single agent treatment in patients with Malignant Pleural Mesothelioma (MPM) in a multicentre phase II European Organization for Research and Treatment of Cancer (EORTC) study. This study enrolled chemonaíve patients with histologically-confirmed measurable MPM. Raltitrexed was administered at the dose of 3 mg/m(2) intravenous (i.v.) bolus on an outpatient basis every 3 weeks. A maximum of eight cycles was planned in cases with an absence of progression or unacceptable toxicity. 24 patients received a total of 104 courses. 5 patients (20.8%, 95% confidence interval (CI) 7.1-42.2%) had a partial response (PR), which was confirmed by an independent radiology committee. Toxicity was mild, with diarrhoea, nausea, vomiting, fatigue and neutropenia as the major side-effects, but not exceeding grade 3 toxicity. We conclude that raltitrexed has activity as a single agent in the treatment of MPM, and that further studies with this drug in MPM are warranted
AB - We investigated the activity and toxicity of raltitrexed (Tomudex) as a single agent treatment in patients with Malignant Pleural Mesothelioma (MPM) in a multicentre phase II European Organization for Research and Treatment of Cancer (EORTC) study. This study enrolled chemonaíve patients with histologically-confirmed measurable MPM. Raltitrexed was administered at the dose of 3 mg/m(2) intravenous (i.v.) bolus on an outpatient basis every 3 weeks. A maximum of eight cycles was planned in cases with an absence of progression or unacceptable toxicity. 24 patients received a total of 104 courses. 5 patients (20.8%, 95% confidence interval (CI) 7.1-42.2%) had a partial response (PR), which was confirmed by an independent radiology committee. Toxicity was mild, with diarrhoea, nausea, vomiting, fatigue and neutropenia as the major side-effects, but not exceeding grade 3 toxicity. We conclude that raltitrexed has activity as a single agent in the treatment of MPM, and that further studies with this drug in MPM are warranted
U2 - https://doi.org/10.1016/S0959-8049(02)00668-8
DO - https://doi.org/10.1016/S0959-8049(02)00668-8
M3 - Article
C2 - 12565988
SN - 0959-8049
VL - 39
SP - 353
EP - 357
JO - European journal of cancer (Oxford, England
JF - European journal of cancer (Oxford, England
IS - 3
ER -